Caitlin Omoregie, PA
Physician Assistant · Cleveland, OHNPI 1669987707
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,160 of the $37,589 with a category attached, or 66.9%. 18 manufacturers reported payments, led by Dexcom, Inc. at 43.1% of the total. Among physician assistant clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 179 payments — averaging $210.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$16K
- Boehringer Ingelheim$11K
- Lilly USA, LLC$8K
- Abbott$701
- AstraZeneca$652
- Corcept Therapeutics$486
- plus $844 from 12 others
What the payments were for
- Consulting fees$3,0698%
- Speaking & faculty fees$25,16067%
- Travel & lodging$4,30711%
- Food & beverage$5,00013%
- Education$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 37 | $16,185 |
| Boehringer Ingelheim | 37 | $10,722 |
| Lilly USA, LLC | 39 | $7,999 |
| Abbott | 26 | $701 |
| AstraZeneca | 8 | $652 |
| Corcept Therapeutics | 5 | $486 |
| Novo Nordisk | 8 | $256 |
| Sanofi-aventis U.S. LLC | 6 | $166 |
| Mannkind Corporation | 1 | $137 |
| Novartis | 4 | $79 |
| AbbVie | 1 | $67 |
| Amryt Pharma Holdings Ltd | 1 | $25 |
| CSL Behring | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Averitas Pharma Inc. | 1 | $20 |
| Sequel Med Tech, LLC | 1 | $15 |
| Clarus Therapeutics Inc. | 1 | $15 |
| Recordati_rare_diseases_inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$13,605
- DEXCOM G6 TRANSMITTER$11,000
- DEXCOM G7 GSS (161)$4,384
- FARXIGA$252
- Korlym$242
- AFREZZA$137
- Ozempic$127
- LOKELMA$127
- FreeStyle Libre 2$123
How this compares
$37,589 in reported general payments places this provider in the 95th percentile of 4,098 physician assistant providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 179 | $245,337 |
| MounjaroTirzepatide | 149 | $183,544 |
| OzempicSemaglutide | 145 | $167,763 |
| FarxigaDapagliflozin Propanediol | 132 | $136,194 |
| JardianceEmpagliflozin | 68 | $78,303 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 54 | $52,664 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 29 | $47,406 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $25,855 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 20 | $21,173 |
| Humalog Kwikpen U-100Insulin Lispro | 77 | $18,387 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 87 | $14,232 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $12,751 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 83 | $9,182 |
| Novolog FlexpenInsulin Aspart | 36 | $8,837 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $8,739 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Insulin Lispro | $7,999 | $429,633340 claims |
| Novo NordiskOzempic | $256 | $167,763145 claims |
| AstraZenecaFarxiga | $652 | $136,194132 claims |
| Boehringer IngelheimJardiance, Trijardy Xr | $10,722 | $99,47588 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,098 physician assistant providers in Ohio.
Other physician assistant in Cleveland
- Michael DombrowskiCleveland$20K
- Tracey MatejkaCleveland$17K
- Malissa AyersCleveland$15K
- Dale NovakCleveland$14K
- Steven WurzelbacherCincinnati$309K
- Emily AnkromDayton$192K
- Amanda MaggartWorthington$164K
- Megan SevillaMayfield Heights$132K
- Erin StrculaBelpre$106K
- Sarah LaubNew Albany$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.